Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Rhea-AI Summary
Rezolute (Nasdaq:RZLT) reported fiscal Q3 2026 results and clinical updates for ersodetug in hyperinsulinism.
Expanded Phase 3 sunRIZE analyses in congenital HI showed CGM-based reductions in hypoglycemia and increased normoglycemia exposure versus placebo. FDA held a Type B meeting and encouraged submission of comprehensive datasets. Tumor HI Phase 3 upLIFT enrollment continues, with topline data expected in 2H 2026.
Cash and investments were $120.3M at March 31, 2026, versus $167.9M at June 30, 2025. Q3 R&D was $11.4M, G&A $6.0M, and net loss $16.2M, all improving or increasing versus the prior-year quarter as specified.
Positive
- Phase 3 sunRIZE CGM data show sizable hypoglycemia reductions versus placebo
- FDA Type B meeting completed; agency requested comprehensive analysis datasets
- Phase 3 upLIFT tumor HI trial enrolling; topline data expected 2H 2026
- Cash, cash equivalents and securities of $120.3M as of March 31, 2026
- R&D expenses decreased to $11.4M from $15.3M year over year
- Net loss narrowed to $16.2M from $18.9M year over year
Negative
- Cash and investments declined to $120.3M from $167.9M since June 30, 2025
- G&A expenses increased to $6.0M from $4.7M year over year
- Share-based compensation rose to $1.9M in R&D and $2.5M in G&A
- Company continues to operate at a quarterly net loss of $16.2M
News Market Reaction – RZLT
In the May 13 session, RZLT gained 0.91%, reflecting a mild positive market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Q2 FY2026 earnings | Negative | +5.8% | Earnings plus Phase 3 sunRIZE miss and higher net loss year over year. |
| Nov 06 | Q1 FY2026 earnings | Positive | +12.1% | Earnings with FDA alignment on registrational plans and clear sunRIZE timeline. |
| Sep 17 | Q4/FY2025 earnings | Positive | +6.4% | Full-year update highlighting sunRIZE enrollment completion and strong cash growth. |
| May 13 | Q3 FY2025 earnings | Positive | -4.9% | Q3 results, Breakthrough Therapy Designation, and capital raise extending runway. |
| Feb 12 | Q2 FY2025 earnings | Positive | -1.0% | Earnings with Breakthrough and Orphan Drug designations and higher R&D spend. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases often drew strong but inconsistent reactions: 3 of 5 past reports showed price moves that diverged from the generally constructive business updates.
Over the last several earnings cycles, Rezolute has highlighted progression of its hyperinsulinism programs and evolving financials. Prior updates featured completion of Phase 3 sunRIZE enrollment, FDA alignment on registrational design for upLIFT, and cash positions ranging from $88.4M to $167.9M. More recent results acknowledged sunRIZE’s failure on primary endpoints while maintaining FDA dialogue. Today’s Q3 FY2026 report continues that pattern, updating cash of $120.3M, lower R&D, and an ongoing focus on ersodetug and tumor HI.
Key Terms
congenital hyperinsulinism medical
continuous glucose monitoring medical
open-label extension medical
type b meeting regulatory
self-monitored blood glucose medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.
Congenital Hyperinsulinism (HI)
- In May 2026, expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented via oral presentation at the Pediatric Endocrine Society (PES) 2026 Annual Meeting by Diva D. De León-Crutchlow, M.D., M.S.C.E., Chief of the Division of Endocrinology and Diabetes, Director of the Congenital Hyperinsulinism Center at Children’s Hospital of Philadelphia, and Principal Investigator of the sunRIZE study.
- In addition to the previously reported topline results, the presentation included results from additional continuous glucose monitoring (CGM)-based outcomes, which demonstrated significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints.
- Average daily percent time in hypoglycemia by CGM: clinically relevant and nominally statistically significant reductions of >
50% (Full Analysis Set [FAS]) and ~60-80% (Per Protocol Set [PPS]), compared to placebo across multiple timepoints - Average weekly hypoglycemia events by CGM: clinically relevant and nominally statistically significant reductions of ~50
-65% (FAS) and ~50-80% (PPS), compared to placebo across multiple timepoints - Average daily AUC 70 to 180 mg/dL (Exposure to Normoglycemia) by CGM: clinically relevant and nominally statistically significant increases of ~25
-50% (FAS and PPS), compared to placebo across multiple timepoints - Average blood glucose (mg/dL) by CGM: clinically relevant and nominally statistically significant increases of ~10
-15% (~10-15 mg/dL) in both the FAS and PPS, compared to placebo across multiple timepoints - Participation, retention, and treatment duration in the open-label extension (OLE) following the completions of the study is high and has resulted in continued glycemic benefit, concurrent with the reduction and/or discontinuation of background standard of care therapies.
- Average daily percent time in hypoglycemia by CGM: clinically relevant and nominally statistically significant reductions of >
- In addition to the previously reported topline results, the presentation included results from additional continuous glucose monitoring (CGM)-based outcomes, which demonstrated significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints.
- In March 2026, Rezolute announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to the sunRIZE study.
- FDA acknowledged the challenges posed by the potential impact of varied behavioral factors on clinical trials in this heterogeneous patient population, including the associated limitations of self-monitored blood glucose (SMBG) based metrics in measuring hypoglycemia in congenital HI.
- FDA encouraged Rezolute to submit comprehensive analysis datasets and summary outcomes for the agency’s independent evaluation.
- The Company expects to have an update on the program in the second half of 2026.
Tumor HI
- upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing.
- Enrollment is in progress and topline results are expected in the second half of 2026.
- In January 2026, the Company shared aggregate data from the initial 9 tumor HI patients treated under the historical Expanded Access Program (EAP). The full EAP data table, filed on Form 8-K with the U.S. Securities and Exchange Commission, can be found here.
Third Quarter Fiscal 2026 Financial Results
Cash, cash equivalents and investments in marketable securities were
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
Net loss was
About Ersodetug
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the predictive nature of the CGM data as it relates to the potential efficacy of ersodetug in treating hypoglycemia, the ability of the Company to provide study reports and analysis datasets for the FDA’s independent evaluation, the persuasiveness of the study reports and analysis datasets and the possibility of FDA agreeing to advance the congenital HI program based on those study reports and analysis datasets notwithstanding the lack of statistical significance in the sunRIZE study. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Rezolute Contacts:
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
cmckim@rezolutebio.com
336-608-9706
| Rezolute, Inc. | |||||||||||||||||||
| Condensed Consolidated Financial Statements Data | |||||||||||||||||||
| (in thousands, except per share data) | |||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||
| March 31, | March 31, | ||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Condensed Consolidated Statements of Operations Data: | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Research and development | $ | 11,412 | $ | 15,283 | $ | 38,909 | $ | 40,664 | |||||||||||
| General and administrative | 5,954 | 4,740 | 22,495 | 13,380 | |||||||||||||||
| Total operating expenses | 17,366 | 20,023 | 61,404 | 54,044 | |||||||||||||||
| Loss from operations | (17,366 | ) | (20,023 | ) | (61,404 | ) | (54,044 | ) | |||||||||||
| Non-operating income, net | 1,195 | 1,109 | 4,309 | 4,022 | |||||||||||||||
| Net loss | $ | (16,171 | ) | $ | (18,914 | ) | $ | (57,095 | ) | $ | (50,022 | ) | |||||||
| Basic and diluted net loss per common share | $ | (0.16 | ) | $ | (0.27 | ) | $ | (0.55 | ) | $ | (0.72 | ) | |||||||
| Shares used to compute basic and diluted net loss per common share | 104,040 | 70,031 | 103,714 | 69,902 | |||||||||||||||
| March 31, | June 30, | ||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||
| Condensed Consolidated Balance Sheets Data: | |||||||||||||||||||
| Cash and cash equivalents | $ | 11,236 | $ | 94,107 | |||||||||||||||
| Investments in marketable debt securities | 109,032 | 73,751 | |||||||||||||||||
| Working capital | 114,345 | 159,233 | |||||||||||||||||
| Total assets | 125,459 | 175,490 | |||||||||||||||||
| Accumulated deficit | (460,951 | ) | (403,856 | ) | |||||||||||||||
| Total stockholders’ equity | 116,834 | 162,127 | |||||||||||||||||
